2024/10/18 08:07:17 | |
---|---|
Price | |
42.78 EUR | |
Difference | -0.81% (-0.35) |
ISIN | JP3519400000 |
Symbol | 4519 |
Exchange | Stuttgart |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 71,083 EUR |
Benchmark | NIKKEI 225 |
Bid (Bid size) | - (0) |
Ask (Ask size) | - (0) |
Open | 42.78 EUR |
High | 42.78 EUR |
Low | 42.78 EUR |
Close (prev. day) | 43.13 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 3 |
Last size | 0 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/09/27 | Global Equity Ratings | ||
2024/09/11 | Global Equity Ratings | ||
2024/09/05 | Global Equity Ratings | ||
2024/08/12 | Global Equity Ratings | ||
2024/07/24 | Global Equity Ratings |
2024/10/18 08:07:17 | |
---|---|
Price | |
42.78 EUR | |
Difference | -0.81% (-0.35) |
ISIN | JP3519400000 |
Symbol | 4519 |
Exchange | Stuttgart |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 71,083 EUR |
Benchmark | NIKKEI 225 |
Bid (Bid size) | - (0) |
Ask (Ask size) | - (0) |
Open | 42.78 EUR |
High | 42.78 EUR |
Low | 42.78 EUR |
Close (prev. day) | 43.13 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 3 |
Last size | 0 |
6m | 1Y | 3Y | |
Perf (%) | +40.26% | +47.52% | +45.26% |
Perf (abs.) | +12.28 | +13.78 | +13.33 |
Beta | 0.66 | 0.69 | 0.76 |
Volatility | 36.79 | 35.63 | 30.97 |
Ø price 5 days | Ø volume 5 days (pcs.) | 43.53 EUR (0) |
Ø price 30 days | Ø volume 30 days (pcs.) | 42.82 EUR (44) |
Ø price 100 days | Ø volume 100 days (pcs.) | 38.09 EUR (18) |
Ø price 250 days | Ø volume 250 days (pcs.) | 34.72 EUR (11) |
YTD High | date | 46.10 EUR (2024/08/27) |
YTD Low | date | 27.04 EUR (2024/05/29) |
52 Weeks High | date | 46.10 EUR (2024/08/27) |
52 Weeks Low | date | 26.80 EUR (2023/10/26) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Tradegate | 2024/10/18 | 22:26 | 43.59 EUR | 0.01 | 4 |
Tokyo Stock Exchange | 2024/10/18 | 08:00 | 7,022.00 JPY | 82.94 | 3,076 |
Stuttgart | 2024/10/18 | 08:07 | 42.78 EUR | 0.00 | 3 |
Munich | 2024/10/18 | 17:26 | 43.09 EUR | 0.00 | 3 |
Hanover | 2024/10/18 | 17:25 | 40.67 EUR | 0.00 | 4 |
Frankfurt | 2024/10/17 | 11:32 | 45.97 EUR | 0.00 | 1 |
FINRA other OTC Issues | 2024/10/18 | 20:37 | 44.92 USD | 0.05 | 19 |
Duesseldorf | 2024/10/18 | 19:31 | 42.78 EUR | 0.00 | 7 |
Berlin | 2024/10/18 | 18:46 | 43.46 EUR | 0.00 | 7 |
CHUGAI PHARMACEUTICAL CO. LTD. |
- - |
Nihonbashi Mitsui Tower, 15/F, 2-1-1 Nihonbashi-Muromachi - 103-8324 Tokyo |
Telefon: +81-3-3281-6611 |
Fax: +81-3-3281-6607 |
E-mail: - |
Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan. |
Osamu Okuda | Chairman of Managing Board |
Hitoshi Ikura | Member of Executive Committee |
Iwaaki Taniguchi | Member of Executive Committee |
Junichi Ebihara | Member of Executive Committee |
Shinji Hidaka | Member of Executive Committee |
Tetsuya Yamaguchi | Member of Executive Committee |
Yoshiyuki Yano | Member of Executive Committee |
Christoph Franz | Member of Supervisory Board |
James Sabry | Member of Supervisory Board |
Iwaaki Taniguchi | Member of Supervisory Board |
Mariko Momoi | Member of Supervisory Board |
Masayuki Oku | Member of Supervisory Board |
Motoo Ueno | Member of Supervisory Board |
William Anderson | Member of Supervisory Board |
Yoichiro Ichimaru | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer